ArticleLupus science & medicine2026
Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJanus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist. Clinical trials in SLE have not consistently demonstrated an increased risk of thrombotic events and the effects of JAK inhibition on platelet function remain incompletely understood.
objectivesTo investigate whether the JAK1 inhibitor upadacitinib modulates platelet procoagulant membrane dynamics (PMD) in vitro and to explore the associated cytokine signatures.
methodsWhole blood from patients with SLE (n=10) and healthy controls (n=10) was preincubated with upadacitinib (0, 60 and 300 ng/mL). Platelet-rich plasma was analysed using confocal microscopy and Volocity software (Quorum Technology) to quantify PMD markers. We used Alexa Fluor 488 CD62p to detect degranulation, Alexa Fluor 568 Annexin-V to detect phosphatidylserine exposure and Alexa Fluor 647 PAC-1 to detect integrin αIIbβ3 activation. Participants were stratified as JAKi-activated or JAKi-null depending on whether PMD markers were amplified on JAK inhibition or remained unaffected. We then used Luminex xMAP technology to quantify 96 human plasma cytokines, chemokines and growth factors.
resultsPlatelet responses were heterogeneous. Approximately 30% of both groups exhibited increased platelet activation and procoagulant responses ('JAKi-activated'), whereas the remainder remained unaffected. Platelets of patients with SLE demonstrated elevated baseline activation, characterised as preactivation or autoactivation. JAKi-activated phenotypes were associated with increased plasma levels of interleukin (IL)-4 and tumour necrosis factor-beta (TNF-β) after JAK inhibition. In vitro, we showed that recombinant IL-4 and TNF-β directly activated platelets or primed platelet responses to procoagulant agonists, supporting a potential indirect mechanism for the enhanced procoagulation observed in our JAKi-activated subpopulations.
conclusionsUpadacitinib was associated with enhanced platelet activation and procoagulant responses in vitro in a subset of individuals with SLE and healthy controls. These findings are preliminary and hypothesis-generating. Further studies are required to determine clinical relevance and validate stratification approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.